We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Relay Therapeutics Inc (RLAY) USD0.001

Sell:$25.72 Buy:$37.00 Change: $1.26 (4.28%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $1.26 (4.28%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $1.26 (4.28%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. The Company is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-1971 and RLY-4008, as well as its PI3Ka mutant selective program (RLY-PI3K1047 program). Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008, is it inhibitor of fibroblast growth factor receptor 2 (FGFR2), enriched for patients with advanced solid tumors having oncogenic FGFR2.

Contact details

399 Binney Street, 2Nd Floor
United States
+1 (617) 3708837

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$3.10 billion
Shares in issue:
108.04 million
United States
US dollar

Key personnel

  • Sanjiv Patel
    President, Chief Executive Officer, Director
  • Donald Bergstrom
    Executive Vice President, Head of Research and Development
  • Thomas Catinazzo
    Senior Vice President - Finance
  • Tara O'Meara
    Senior Vice President of Clinical Development Operations
  • Charles Ferte
    Vice President, Global Medical Lead
  • Brian Adams
    General Counsel, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.